Collaboration has always been a key component of cancer research. To comprehend the intricate biology of cancer and develop new strategies for treatment, researchers, clinicians, analysts, and pharmaceutical researchers must work in unison. Healthcare interoperability has grown immensely in the past few years, along with research collaboration. Interoperability fuels research quality and discovery by offering new avenues for the collaboration of disparate healthcare systems and research platforms.
As the cancer industry becomes more personalized and the available treatments more data-rich, research collaboration will need to expand. Interoperability provides research collaborators with the information and the ability to integrate previously siloed data into their work and push forward the understanding of cancer.
What is Healthcare Interoperability?
When different digital health systems can share, interpret, and utilize medical data, they are said to be interoperable. Examples of digital health systems are electronic health records (EHRs), laboratory systems, imaging systems, and research databases.
In the past, healthcare systems used to isolate their data and store it in ways that made it impossible to communicate. This would mean for a hospital electronic record system, it may be incompatible with a research data system. In these situations, the data, especially clinical data, would be closed off to researchers who are working on developing new therapies.
Interoperability is used to solve the problem of communication by developing standards and technologies that enable various systems to work together. The most common standards for interoperability include:
- HL7 and FHIR in relation to structured data exchange in healthcare
- DICOM in relation to medical imaging data
- Clinical data repositories that integrate data from several different institutions
With these systems, researchers have access to larger and more varied data sets.
The Role of Data in Cancer Research
Data is the most critical element for the successful outcome of a clinical research protocol. Cancer research is a unique example of clinical research that illustrates the absolute dependence on data for research to be conducted. This is because cancer is not a disease but dozens, hundreds, and even thousands of separate entities that have all the variability in genetics and biology that one can imagine. The variability with cancer is extremely high and demands researchers to have access to data that is extremely wide. The data available to researchers in cancer research is also very high. Data availability is one of the essential elements that generate the successful outcome of a clinical research protocol.
The healthcare system interoperability facilitate data retrieval from:
- hospitals and cancer centers
- clinical trial databases
- genomics laboratories
- public health databases
- research universities
Researchers can answer their research questions using data from multiple databases and large populations of patients. Using data from a small population of patients prevents researchers from answering their questions. Greater data leads to better research and better research leads to better clinical practices. Shared clinical data aids researchers in improving their clinical practices and identifying and measuring the effects of clinical procedures.
Research and Development Interoperability
Research and clinical trials develop new cancer treatments. However, research and clinical trials have patient recruitment, data collection, and data retention challenges. Interoperability tackles these recruitment, data retention, and data collection challenges by enabling the retention and collection of data within and from multiple health centers.
Interoperability enhances data retention and collection simplicity by allowing patients to transfer data to a clinical trial process rather than manually providing the data.
At last, the interoperability will assist in tracking the patient outcomes beyond the completion of the trial. Researchers will look at the actual health data to see how effective new treatment options are.
Supporting Drug Repurposing Research
Interoperability is also critical in the area of drug repurposing research. Drug repurposing is when researchers look for new positive effects for other diseases of drugs that were developed for other purposes.
In cancer research, drug repurposing is important because it can help researchers come up with new treatments much faster and at a much lower cost. Researchers do not have to start a new treatment from scratch, they just have to look at unknown benefits of already existing drugs that have known safety and effective records.
Some anti parasitic drugs have also been looked at in the lab to see if they can impact cancer cells. When people talk about new ways of drug repurposing, they are talking about how researchers are studying certain drugs that can impact cancer cells’ microtubules and cellular metabolism, and one of the drugs that come up is fenbendazole 444 mg capsules.
Interoperability is helping researchers to cross other studies more efficiently to learn about other drugs and cancer pathways.
Data Collection and Personalized Precision Oncology
Genomic and precision data generated by modern tumor sequencing technologies are used in personalized precision oncology, which is an emerging subtype of oncology that involves tailoring treatment for each individual depending on their tumor’s unique genetic makeup. On a large scale, profuse data are produced in sequencing of DNA, RNA, and proteins, molecular mechanisms related to the development of malignancies, and molecular pathways.
Nonetheless, a tremendous amount of genomic data is only helpful if available and decipherable. The ability to exchange information (in this case, the genomic data) and the data from the clinical records, the images, and the history of treatments received.
This allows researchers to
- Establish a relationship between certain genetic mutations and the type of cancer.
- Anticipate which targeted therapy the patient is likely to respond to.
- Identify new biomarkers for early-stage cancer.
- Construct individualized treatment approaches that are more effective.
The ability to exchange information, by linking genomic systems and clinical systems, provides a more comprehensive perspective in cancer systems.
Obstacles to Fully Achieving Interoperability
Interoperability in health care has a lot of benefits, but implementing it on a grand scale has its limitations, including:
- Concerns regarding security and privacy of data
- Different software systems in use by different hospitals
- No universal guidelines in some areas
- High costs involved in modernizing old technology
Health care organizations must find a balance between sharing data and protecting privacy. In order to mitigate risks associated with having patient information, regulations like HIPAA in the US and GDPR in Europe exist.
The Future of Collaborative Cancer Research
With the advancement of technology in health care, cancer research will emphasize more on interoperability than before. Critical technologies like artificial intelligence, machine learning, and advanced analytics depend on large data sets to fuel their operations.
When data from hospitals, laboratories, and other research institutions is able to be integrated and analyzed, scientists will be able to more rapidly find new solutions to problems, and increase the number of patients that can be helped.
Foremost, they will likely incorporate:
- Global cancer networks with interoperable systems to enhance cancer research
- AI tools for analyzing shared health data
- Integrated databases for genomics and clinical data
- Accelerated partnerships for pharma and research entities
This list signifies the potential for profoundly changing impact on how cancer research is done and how quickly it will take to get more treatment options to patients.
Conclusion
When it comes to the modern-day collaboration of cancer research, the value of the interoperability of different healthcare systems cannot be overstated. It is the value of cancer research collaboration. It is the value of the research collaboration that increases or enhances the value of the clinical research collaboration. It is the value of the research collaboration that facilitates the Repurposing of Unused Drugs for Clinical Trials. It is the value of the research collaboration that it is the value of the research collaboration.
Interoperability, along with improvement in data-sharing standards, will continue to be the foundation of joint medical research and the modern cancer research collaboration. These collaborative systems are finger posted for primary healthcare to ease the global research on cancer and prolongs the life of cancer patients.
